Patients with CAN had higher body weight (69.8 ± 12.4 vs. 61.9 ± 10.5) (p = 0.047), higher BMI (27.8 ± 5.9 vs. 24.9 ± 3.7) (p = 0.046), lower hematocrit (30.5 ± 4.4 vs. 36.2 ± 4.6) (p = 0.001), higher creatinine (1.4 (1.2,1.4) vs. 0.9 (0.7,1.2)) (p = 0.003), higher usage of insulin (50% vs. 11.9%) (p = 0.017), longer duration of DM (18.5(15,25.8) vs. 10 (4,15)) (p = 0.006), and more usage of angiotensin receptor blocker (ARB) (62.5% vs. 13.1%) (p = 0.004) than those without CAN (Table 1). This evidence concerns the gene INS and diabetes mellitus.